Teduglutide dosage in published studies and labels

These are the doses used for Teduglutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Teduglutide has an FDA-approved human dosage. Gattex for short bowel syndrome in adults and children aged 1 and over who depend on parenteral support is 0.05 mg/kg once daily under the skin. With an eGFR under 60 mL/min/1.73 m² the dose is 0.025 mg/kg once daily.

FDA Approved

Dosage evidence summary for Teduglutide
Human dosing established	Yes
Studied dose range	0.05 mg/kg once daily (0.025 mg/kg with reduced kidney function)
Route	Subcutaneous
Frequency	Once daily
Duration studied	Continuous, with colonoscopy and lab checks
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Teduglutide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Gattex, short bowel syndromeFDA-approved label · FDA prescribing information	Adults and children aged 1 year and older with short bowel syndrome who depend on parenteral support	0.05 mg/kg	Subcutaneous, rotating abdomen, thighs or arms	Once daily	Continuous	Treatment of short bowel syndrome	GATTEX (teduglutide) for injection — FDA prescribing information, DailyMed
FDA label — Gattex, reduced kidney functionFDA-approved label · FDA prescribing information	Adults and children with moderate or severe renal impairment or end-stage renal disease (eGFR under 60 mL/min/1.73 m²)	0.025 mg/kg	Subcutaneous	Once daily	Continuous	Treatment of short bowel syndrome	GATTEX (teduglutide) for injection — FDA prescribing information, DailyMed

Where sources disagree

Gattex is a powder that is mixed with the supplied diluent before each injection; it is a prescription kit, not a vial product in this library's shop.
The label requires a colonoscopy and upper GI endoscopy in adults (fecal occult blood testing in children) within 6 months before starting, with polyps removed. Its warnings list acceleration of neoplastic growth, and say to stop Gattex if an intestinal malignancy is found.